Pharmacodynamics<unk>  has been found to possess similar affinity for the progesterone receptor and androgen receptor, and in accordance, has some androgenic activity. The androgenic activity of<unk>  is greater than that of other 19-nortestosterone derivatives due to the presence of the C9(11) double bond, which enhances said activity. The ratio of progestogenic to androgenic activity appears to be much lower for<unk>  that it is for other 19-nortestosterone progestins such as norethisterone and levonorgestrel. Gestrinone, the 18-methyl analogue of<unk> , has even greater androgenic activity than<unk> , as this modification increases androgenic activity similarly. Relative affinities (%) of<unk>  and related steroids Compound Norethisterone 155–156 43–45 <0.1 2.7–2.8 0.2 ? ?<unk>  63–65 70 <0.1 11 1.8 ? ? Levonorgestrel 170 84–87 <0.1 14 0.6–0.9 ? ? Gestrinone 75–76 83–85 <0.1, 3–10 77 3.2 ? ? Notes: Values are percentages (%). Reference ligands (100%) were progesterone for the , testosterone for the , for the , for the , aldosterone for the , for , and cortisol for . Sources: Pharmacokinetics The metabolism of<unk>  in humans has been studied.
Norgestrienone
Lapisteride
Androstanolone enanthate
Quingestanol acetate
Norvinisterone
Segesterone acetate
Androstanolone propionate
Ethylestrenol